Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 1, 2011, Pages

  Wansapura, Arshani N ^a   Lasko, Valerie M ^a   Lingrel, Jerry B ^a   Lorenz, John N ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiotonic steroids; Fibrosis; Heart failure; Transverse aortic coarctation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA 1; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA 2; CARDIOTONIC AGENT; OUABAIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA COARCTATION; ARTICLE; CONGESTIVE HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARDIOMEGALY; ECHOCARDIOGRAPHY; GENOTYPE; HEMODYNAMICS; MICE; MICE, TRANSGENIC; OUABAIN; PROTEIN ISOFORMS; SODIUM-POTASSIUM-EXCHANGING ATPASE; VENTRICULAR FUNCTION, LEFT;

EID: 78651334920     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00625.2010     Document Type: Article

References (43)

1. +-ATPase in the inotropic action of digitalis. Pharmacol Rev 29: 187-220, 1977.
2. +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31: 1097-1103, 1998.
3. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, L'Abbate A. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 3: 165-171, 2001.
4. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113: 799-805, 2006.
5. Dostanic I, Lorenz JN, Schultz Jel J, Grupp IL, Neumann JC, Wani MA, Lingrel JB. The α2 isoform of Na,K-ATPase mediates ouabain-induced cardiac inotropy in mice. J Biol Chem 278: 53026-53034, 2003.
6. Dostanic I, Schultz Jel J, Lorenz JN, Lingrel JB. The α1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart. J Biol Chem 279: 54053-54061, 2004.
7. +-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol 290: R524-R528, 2006.
8. Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci USA 102: 15845-15850, 2005.
9. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49: 215-224, 2007.
10. Elkareh J, Periyasamy SM, Shidyak A, Vetteth S, Schroeder J, Raju V, Hariri IM, El-Okdi N, Gupta S, Fedorova L, Liu J, Fedorova OV, Kahaleh MB, Xie Z, Malhotra D, Watson DK, Bagrov AY, Shapiro JI. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol 296: F1219-F1226, 2009.
11. Fishman MC. Endogenous digitalis-like activity in mammalian brain. Proc Natl Acad Sci USA 76: 4661-4663, 1979.
12. Fridman AI, Matveev SA, Agalakova NI, Fedorova OV, Lakatta EG, Bagrov AY. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 20: 1189-1194, 2002.
13. Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am Heart J 134: 3-12, 1997.
14. Goto A, Ishiguro T, Yamada K, Ishii M, Yoshioka M, Eguchi C, Shimora M, Sugimoto T. Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun 173: 1093-1101, 1990.
15. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420-425, 1992.
16. Gruber KA, Whitaker JM, Buckalew VM Jr. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature 287: 743-745, 1980.
17. +-ATPase. J Biol Chem 275: 27832-27837, 2000.
18. +-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem 277: 18694-18702, 2002.
19. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 88: 6259-6263, 1991.
20. Haupert GT Jr, Sancho JM. Sodium transport inhibitor from bovine hypothalamus. Proc Natl Acad Sci USA 76: 4658-4660, 1979.
21. Huang L, Kometiani P, Xie Z. Differential regulation of Na/K-ATPase α-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. J Mol Cell Cardiol 29: 3157-3167, 1997.
22. Huang L, Li H, Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. J Mol Cell Cardiol 29: 429-437, 1997.
23. James PF, Grupp IL, Grupp G, Woo AL, Askew GR, Croyle ML, Walsh RA, Lingrel JB. Identification of a specific role for the Na,K-ATPase α2 isoform as a regulator of calcium in the heart. Mol Cell 3: 555-563, 1999.
24. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 294: F450-F454, 2008.
25. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006.
26. Kusuoka H, Hoffman JI. Advice on statistical analysis for Circulation Research. Circ Res 91: 662-671, 2002.
27. Kuznetsova T, Manunta P, Casamassima N, Messaggio E, Jin Y, Thijs L, Richart T, Fagard RH, Bianchi G, Staessen JA. Left ventricular geometry and endogenous ouabain in a Flemish population. J Hypertens 27: 1884-1891, 2009.
28. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 135: 794-797, 1994.
29. Lichtstein D, Samuelov S. Endogenous 'ouabain like' activity in rat brain. Biochem Biophys Res Commun 96: 1518-1523, 1980.
30. Liu L, Zhao X, Pierre SV, Askari A. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes. Am J Physiol Cell Physiol 293: C1489-C1497, 2007.
31. Lorenz JN. A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. Am J Physiol Regul Integr Comp Physiol 282: R1565-R1582, 2002.
32. +-ATPase subunit. Am J Physiol Heart Circ Physiol 295: H273-H280, 2008.
33. Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol Heart Circ Physiol 272: H1137-H1146, 1997.
34. 2+- dependent expressions of early-response genes in cardiac myocytes. J Biol Chem 271: 10372-10378, 1996.
35. Pierdomenico SD, Bucci A, Manunta P, Rivera R, Ferrandi M, Hamlyn JM, Lapenna D, Cuccurullo F, Mezzetti A. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am J Hypertens 14: 44-50, 2001.
36. Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 8: 602-610, 1995.
37. Pullen MA, Brooks DP, Edwards RM. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids. J Pharmacol Exp Ther 310: 319-325, 2004.
38. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
39. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW 2nd. Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 97: 1488-1495, 1998.
40. Skoumal R, Szokodi I, Aro J, Foldes G, Gooz M, Seres L, Sarman B, Lako-Futo Z, Papp L, Vuolteenaho O, Leppaluoto J, DeChatel R, Ruskoaho H, Toth M. Involvement of endogenous ouabain-like compound in the cardiac hypertrophic process in vivo. Life Sci 80: 1303-1310, 2007.
41. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533, 1997.
42. +-ATPase. Am J Physiol Heart Circ Physiol 296: H1833-H1839, 2009.
43. +)-ATPase activity of isolated or cultured cells. Anal Biochem 183: 215-219, 1989.